Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	NT$56.90	-0.70%	81,614
13/26/13	NT$57.30	+2.14%	1,08,313
12/26/12	NT$56.10	-0.71%	56,905
11/26/11	NT$56.50	+1.44%	57,833
10/26/10	NT$55.70	+1.27%	46,351

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. 14/08/2026			5-day change	1st Jan Change
56.90 ^TWD	-0.70%		+5.37%	-4.37%

12/08	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/07	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT

Market Cap	439.75Cr 14Cr 12Cr 11Cr 10Cr 19Cr 1.31TCr 19Cr 130.7Cr 51Cr 658.13Cr 52Cr 50Cr 2.19TCr	P/E 2024	-31x	P/E 2025	-22.2x
Enterprise Value	697.12Cr 22Cr 19Cr 18Cr 16Cr 30Cr 2.08TCr 31Cr 207.2Cr 81Cr 1.04TCr 82Cr 80Cr 3.47TCr	EV / Sales 2024	3.48x	EV / Sales 2025	3.58x
Free-Float	47.17%	Yield 2024 *	-	Yield 2025	-

12/08	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/07	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
14/05	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/03	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/11	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/25/12	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
17/25/17	Bionime Corporation Approves Amendment to the Article of Incorporation	CI
12/25/12	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/25/10	Bionime Sees No Impact from US Reciprocal Tariffs	MT
12/24/12	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/24/14	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
08/24/08	Bionime Corporation Announces Financial Officer Changes	CI
28/24/28	Bionime Corporation Approves Cash Dividends, Payable on August 23, 2024	CI

02/22/02	Bionime Announces the Introduction of Its Revolutionary iFree CGM for Diabetes Management Coming Soon	AQ
01/22/01	Bionime Corporation to Launch the Rightest iFree CGM, Proposed to Offer Precise and Accurate Blood Glucose Measurement and Monitoring	AQ
25/22/25	Bionime RIGHTEST iFree CGM System - An Innovative Approach to Keep Track of Every One Health	AQ
04/22/04	Bionime : Announcement of change the Globle Sales Division officer of the company.	PU
05/22/05	Bionime : Announcement of members of the first order audit committee of the Company.	PU

Bionime Corporation Share Price

Stocks

4737

TW0004737002

Medical Equipment, Supplies & Distribution

Valuation: Bionime Corporation

Chart: Bionime Corporation

Latest news : Bionime Corporation

Press Releases: Bionime Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Bionime Corporation

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-0.70%
1 week	+5.37%
Current month	+1.61%
1 month	-10.53%
3 months	-1.90%
6 months	+1.79%
Current year	-4.37%

1 week	54.9	58
1 month	53.6	60.4
Current year	49.75	72.9
1 year	49.75	73.9
3 years	43.14	81.92
5 years	43.14	88.92
10 years	40	88.92

Manager	Title	Age	Since
Chun Mu Huang CEO	Chief Executive Officer	-	09/07/2010
Hui Chen Chen DFI	Director of Finance/CFO	-	06/11/2017
Zhi Long Yeh CTO	Chief Tech/Sci/R&D Officer	-	07/11/2018

Director	Title	Age	Since
Chun Mu Huang CHM	Chairman	-	14/04/2003
Tai Hsiung Chiang BRD	Director/Board Member	-	17/10/2007
Chien Hsing Lin BRD	Director/Board Member	-	28/06/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIONIME CORPORATION	-0.70%	+5.37%	-16.00%	-14.39%	14Cr
GUARDANT HEALTH, INC.	-1.46%	-0.23%	+168.41%	+341.73%	2.14TCr
BIOMÉRIEUX	+0.14%	+0.83%	-42.08%	-22.18%	991.18Cr
10X GENOMICS, INC.	-3.54%	+23.00%	+313.34%	+10.89%	757.64Cr
LANTHEUS HOLDINGS, INC.	+0.01%	-0.12%	+87.67%	+46.30%	658.86Cr
CARIS LIFE SCIENCES, INC.	-1.71%	+9.00%	-36.41%	-	626.8Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+3.22%	+9.16%	-11.55%	-7.07%	578.29Cr
ANDON HEALTH CO., LTD.	+1.19%	+2.58%	+83.02%	+104.96%	449.91Cr
DIASORIN S.P.A.	-0.64%	-0.05%	-10.60%	-18.67%	427.72Cr
AUTOBIO DIAGNOSTICS CO., LTD.	+3.92%	+5.19%	-20.14%	-33.07%	274.51Cr
Average	+0.10%	+5.13%	+51.57%	+45.39%	691.97Cr
Weighted average by Cap.	-0.45%	+5.07%	+88.39%	+123.04%

	2024	2025
Net sales	193.37Cr 6.04Cr 5.22Cr 4.91Cr 4.46Cr 8.39Cr 577.91Cr 8.53Cr 57Cr 22Cr 289.4Cr 23Cr 22Cr 961.72Cr	183.86Cr 5.75Cr 4.96Cr 4.66Cr 4.24Cr 7.97Cr 549.47Cr 8.11Cr 55Cr 21Cr 275.16Cr 22Cr 21Cr 914.39Cr
Net income	-13Cr -39.76L -34.34L -32.27L -29.35L -55.18L -38Cr -56.09L -3.78Cr -1.48Cr -19Cr -1.49Cr -1.46Cr -63Cr	-18Cr -56.34L -48.66L -45.73L -41.59L -78.19L -54Cr -79.48L -5.36Cr -2.09Cr -27Cr -2.12Cr -2.07Cr -90Cr
Net Debt	278.4Cr 8.7Cr 7.52Cr 7.06Cr 6.42Cr 12Cr 832.02Cr 12Cr 83Cr 32Cr 416.65Cr 33Cr 32Cr 1.38TCr	257.37Cr 8.04Cr 6.95Cr 6.53Cr 5.94Cr 11Cr 769.16Cr 11Cr 76Cr 30Cr 385.17Cr 30Cr 30Cr 1.28TCr